From Wikipedia, the free encyclopedia
Pharmaceutical drug classification
Pharmaceutical drug classification
ATC code L01 Antineoplastic agents is a therapeutic subgroup of the
Anatomical Therapeutic Chemical Classification System , a system of alphanumeric codes developed by the
World Health Organization (WHO) for the classification of
drugs and other medical products.
[1]
[2]
[3] Subgroup L01 is part of the anatomical group
L Antineoplastic and immunomodulating agents .
[4]
Codes for
veterinary use (
ATCvet codes ) can be created by placing the letter Q in front of the human ATC code: for example, QL01 .
[5] ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list. National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
L01A Alkylating agents
L01AA Nitrogen mustard analogues
L01AA01
Cyclophosphamide
L01AA02
Chlorambucil
L01AA03
Melphalan
L01AA05
Chlormethine
L01AA06
Ifosfamide
L01AA07
Trofosfamide
L01AA08
Prednimustine
L01AA09
Bendamustine
L01AA10
Melphalan flufenamide
L01AB Alkyl sulfonates
L01AB01
Busulfan
L01AB02
Treosulfan
L01AB03
Mannosulfan
L01AC Ethylene imines
L01AC01
Thiotepa
L01AC02
Triaziquone
L01AC03
Carboquone
L01AD Nitrosoureas
L01AD01
Carmustine
L01AD02
Lomustine
L01AD03
Semustine
L01AD04
Streptozocin
L01AD05
Fotemustine
L01AD06
Nimustine
L01AD07
Ranimustine
L01AD08
Uramustine
L01AG Epoxides
L01AG01
Etoglucid
L01AX Other alkylating agents
L01AX01
Mitobronitol
L01AX02
Pipobroman
L01AX03
Temozolomide
L01AX04
Dacarbazine
L01B Antimetabolites
L01BA Folic acid analogues
L01BA01
Methotrexate
L01BA03
Raltitrexed
L01BA04
Pemetrexed
L01BA05
Pralatrexate
L01BB Purine analogues
L01BB02
Mercaptopurine
L01BB03
Tioguanine
L01BB04
Cladribine
L01BB05
Fludarabine
L01BB06
Clofarabine
L01BB07
Nelarabine
QL01BB90
Rabacfosadine
L01BC Pyrimidine analogues
L01BC01
Cytarabine
L01BC02
Fluorouracil
L01BC03
Tegafur
L01BC04
Carmofur
L01BC05
Gemcitabine
L01BC06
Capecitabine
L01BC07
Azacitidine
L01BC08
Decitabine
L01BC09
Floxuridine
L01BC52 Fluorouracil, combinations
L01BC53 Tegafur, combinations
L01BC58 Decitabine, combinations
L01BC59
Trifluridine , combinations
L01C Plant alkaloids and other natural products
L01CA Vinca alkaloids and analogues
L01CA01
Vinblastine
L01CA02
Vincristine
L01CA03
Vindesine
L01CA04
Vinorelbine
L01CA05
Vinflunine
L01CA06
Vintafolide
L01CB Podophyllotoxin derivatives
L01CB01
Etoposide
L01CB02
Teniposide
L01CC Colchicine derivatives
L01CC01
Demecolcine
L01CD Taxanes
L01CD01
Paclitaxel
L01CD02
Docetaxel
L01CD03
Paclitaxel poliglumex
L01CD04
Cabazitaxel
L01CD51 Paclitaxel and
encequidar
L01CE Topoisomerase 1 (TOP1) inhibitors
L01CE01
Topotecan
L01CE02
Irinotecan
L01CE03
Etirinotecan pegol
L01CE04
Belotecan
L01CX Other plant alkaloids and natural products
L01CX01
Trabectedin
L01D Cytotoxic antibiotics and related substances
L01DA Actinomycines
L01DA01
Dactinomycin
L01DB Anthracyclines and related substances
L01DB01
Doxorubicin
L01DB02
Daunorubicin
L01DB03
Epirubicin
L01DB04
Aclarubicin
L01DB05
Zorubicin
L01DB06
Idarubicin
L01DB07
Mitoxantrone
L01DB08
Pirarubicin
L01DB09
Valrubicin
L01DB10
Amrubicin
L01DB11
Pixantrone
L01DC Other cytotoxic antibiotics
L01DC01
Bleomycin
L01DC02
Plicamycin
L01DC03
Mitomycin
L01DC04
Ixabepilone
L01E Protein kinase inhibitors
L01EA BCR-ABL tyrosine kinase inhibitors
L01EA01
Imatinib
L01EA02
Dasatinib
L01EA03
Nilotinib
L01EA04
Bosutinib
L01EA05
Ponatinib
L01EA06
Asciminib
L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
L01EB01
Gefitinib
L01EB02
Erlotinib
L01EB03
Afatinib
L01EB04
Osimertinib
L01EB05
Rociletinib
L01EB06
Olmutinib
L01EB07
Dacomitinib
L01EB08
Icotinib
L01EB09
Lazertinib
L01EB10
Mobocertinib
L01EB11
Aumolertinib
L01EC B-Raf serine-threonine kinase (BRAF) inhibitors
L01EC01
Vemurafenib
L01EC02
Dabrafenib
L01EC03
Encorafenib
L01ED Anaplastic lymphoma kinase (ALK) inhibitors
L01ED01
Crizotinib
L01ED02
Ceritinib
L01ED03
Alectinib
L01ED04
Brigatinib
L01ED05
Lorlatinib
L01EE Mitogen-activated protein kinase (MEK) inhibitors
L01EE01
Trametinib
L01EE02
Cobimetinib
L01EE03
Binimetinib
L01EE04
Selumetinib
L01EF Cyclin-dependent kinase (CDK) inhibitors
L01EF01
Palbociclib
L01EF02
Ribociclib
L01EF03
Abemaciclib
L01EG Mammalian target of rapamycin (mTOR) kinase inhibitors
L01EG01
Temsirolimus
L01EG02
Everolimus
L01EG03
Ridaforolimus
L01EG04
Sirolimus
L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors
L01EH01
Lapatinib
L01EH02
Neratinib
L01EH03
Tucatinib
L01EJ Janus-associated kinase (JAK) inhibitors
L01EJ01
Ruxolitinib
L01EJ02
Fedratinib
L01EJ03
Pacritinib
L01EJ04
Momelotinib
L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
L01EK01
Axitinib
L01EK02
Cediranib
L01EK03
Tivozanib
L01EK04
Fruquintinib
L01EL Bruton's tyrosine kinase (BTK) inhibitors
L01EL01
Ibrutinib
L01EL02
Acalabrutinib
L01EL03
Zanubrutinib
L01EL04
Orelabrutinib
L01EL05
Pirtobrutinib
L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors
L01EM01
Idelalisib
L01EM02
Copanlisib
L01EM03
Alpelisib
L01EM04
Duvelisib
L01EM05
Parsaclisib
L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors
L01EN01
Erdafitinib
L01EN02
Pemigatinib
L01EN03
Infigratinib
L01EN04
Futibatinib
L01EX Other protein kinase inhibitors
L01EX01
Sunitinib
L01EX02
Sorafenib
L01EX03
Pazopanib
L01EX04
Vandetanib
L01EX05
Regorafenib
L01EX06
Masitinib
L01EX07
Cabozantinib
L01EX08
Lenvatinib
L01EX09
Nintedanib
L01EX10
Midostaurin
L01EX11
Quizartinib
L01EX12
Larotrectinib
L01EX13
Gilteritinib
L01EX14
Entrectinib
L01EX15
Pexidartinib
L01EX17
Capmatinib
L01EX18
Avapritinib
L01EX19
Ripretinib
L01EX21
Tepotinib
L01EX22
Selpercatinib
L01EX23
Pralsetinib
L01EX24
Surufatinib
L01EX25
Umbralisib
L01EX26
Sitravatinib
L01EX27
Capivasertib
QL01EX90
Toceranib
L01F Monoclonal antibodies and antibody drug conjugates
L01FA CD20 (clusters of differentiation 20) inhibitors
L01FA01
Rituximab
L01FA02
Ofatumumab
L01FA03
Obinutuzumab
L01FB CD22 (clusters of differentiation 22) inhibitors
L01FB01
Inotuzumab ozogamicin
L01FB02
Moxetumomab pasudotox
L01FC CD38 (clusters of differentiation 38) inhibitors
L01FC01
Daratumumab
L01FC02
Isatuximab
L01FD HER2 (human epidermal growth factor receptor 2) inhibitors
L01FD01
Trastuzumab
L01FD02
Pertuzumab
L01FD03
Trastuzumab emtansine
L01FD04
Trastuzumab deruxtecan
L01FD05
Trastuzumab duocarmazine
L01FD06
Margetuximab
L01FE EGFR (epidermal growth factor receptor) inhibitors
L01FE01
Cetuximab
L01FE02
Panitumumab
L01FE03
Necitumumab
L01FF PD-1/PDL-1 (programmed cell death protein 1/ death ligand 1) inhibitors
L01FF01
Nivolumab
L01FF02
Pembrolizumab
L01FF03
Durvalumab
L01FF04
Avelumab
L01FF05
Atezolizumab
L01FF06
Cemiplimab
L01FF07
Dostarlimab
L01FF08
Prolgolimab
L01FF09
Tislelizumab
L01FF10
Retifanlimab
L01FF11
Sugemalimab
L01FF12
Serplulimab
L01FF13
Toripalimab
L01FG VEGF/VEGFR (vascular endothelial growth factor) inhibitors
L01FG01
Bevacizumab
L01FG02
Ramucirumab
L01FX Other monoclonal antibodies and antibody drug conjugates
L01FX01
Edrecolomab
L01FX02
Gemtuzumab ozogamicin
L01FX03
Catumaxomab
L01FX04
Ipilimumab
L01FX05
Brentuximab vedotin
L01FX06
Dinutuximab beta
L01FX07
Blinatumomab
L01FX08
Elotuzumab
L01FX09
Mogamulizumab
L01FX10
Olaratumab
L01FX11
Bermekimab
L01FX12
Tafasitamab
L01FX13
Enfortumab vedotin
L01FX14
Polatuzumab vedotin
L01FX15
Belantamab mafodotin
L01FX16
Oportuzumab monatox
L01FX17
Sacituzumab govitecan
L01FX18
Amivantamab
L01FX19
Sabatolimab
L01FX20
Tremelimumab
L01FX21
Naxitamab
L01FX22
Loncastuximab tesirine
L01FX23
Tisotumab vedotin
L01FX24
Teclistamab
L01FX25
Mosunetuzumab
L01FX26
Mirvetuximab soravtansine
L01FX27
Epcoritamab
L01FX28
Glofitamab
L01FX29
Talquetamab
L01FY Combinations of monoclonal antibodies and antibody drug conjugates
L01FY01
Pertuzumab and trastuzumab
L01FY02
Nivolumab and relatlimab
L01FY03
Prolgolimab and
nurulimab
L01X Other antineoplastic agents
L01XA Platinum compounds
L01XA01
Cisplatin
L01XA02
Carboplatin
L01XA03
Oxaliplatin
L01XA04
Satraplatin
L01XA05
Polyplatillen
L01XB Methylhydrazines
L01XB01
Procarbazine
L01XD Sensitizers used in photodynamic/radiation therapy
L01XD01
Porfimer sodium
L01XD03
Methyl aminolevulinate
L01XD04
Aminolevulinic acid
L01XD05
Temoporfin
L01XD06
Efaproxiral
L01XD07
Padeliporfin
L01XF Retinoids for cancer treatment
L01XF01
Tretinoin
L01XF02
Alitretinoin
L01XF03
Bexarotene
L01XG Proteasome inhibitors
L01XG01
Bortezomib
L01XG02
Carfilzomib
L01XG03
Ixazomib
L01XH Histone deacetylase (HDAC) inhibitors
L01XH01
Vorinostat
L01XH02
Romidepsin
L01XH03
Panobinostat
L01XH04
Belinostat
L01XH05
Entinostat
L01XJ Hedgehog pathway inhibitors
L01XJ01
Vismodegib
L01XJ02
Sonidegib
L01XJ03
Glasdegib
L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors
L01XK01
Olaparib
L01XK02
Niraparib
L01XK03
Rucaparib
L01XK04
Talazoparib
L01XK05
Veliparib
L01XK06
Pamiparib
L01XK52 Niraparib and
abiraterone
L01XL Antineoplastic cell and gene therapy
L01XL01
Sitimagene ceradenovec
L01XL02
Talimogene laherparepvec
L01XL03
Axicabtagene ciloleucel
L01XL04
Tisagenlecleucel
L01XL05
Ciltacabtagene autoleucel
L01XL06
Brexucabtagene autoleucel
L01XL07
Idecabtagene vicleucel
L01XL08
Lisocabtagene maraleucel
L01XL09
Tabelecleucel
L01XL10
Nadofaragene firadenovec
L01XL11
Lifileucel
L01XX Other antineoplastic agents
L01XX01
Amsacrine
L01XX02
Asparaginase
L01XX03
Altretamine
L01XX05
Hydroxycarbamide
L01XX07
Lonidamine
L01XX08
Pentostatin
L01XX10
Masoprocol
L01XX11
Estramustine
L01XX16
Mitoguazone
L01XX18
Tiazofurine
L01XX23
Mitotane
L01XX24
Pegaspargase
L01XX27
Arsenic trioxide
L01XX29
Denileukin diftitox
L01XX33
Celecoxib
L01XX35
Anagrelide
L01XX36
Oblimersen
L01XX40
Omacetaxine mepesuccinate
L01XX41
Eribulin
L01XX44
Aflibercept
L01XX46
Olaparib
L01XX52
Venetoclax
L01XX53
Vosaroxin
L01XX57
Plitidepsin
L01XX58
Epacadostat
L01XX59
Enasidenib
L01XX62
Ivosidenib
L01XX66
Selinexor
L01XX67
Tagraxofusp
L01XX69
Lurbinectedin
L01XX72
Tazemetostat
L01XX73
Sotorasib
L01XX74
Belzutifan
L01XX75
Tebentafusp
L01XX77
Adagrasib
L01XX78
Navitoclax
L01XX79
Eflornithine
L01XX80
Imetelstat
QL01XX91
Tigilanol tiglate
QL01XX92
Verdinexor
L01XY Combinations of antineoplastic agents
L01XY01
Cytarabine and daunorubicin
References
CI
monoclonal antibodies ("-mab")
Tyrosine kinase inhibitors ("-nib")
Receptor tyrosine kinase
RET inhibitors:
Entrectinib (ALK, ROS1, NTRK),
Futibatinib (FGFR2),
Infigratinib ,
Larotrectinib (NTRK),
Pemigatinib (FGFR),
Pralsetinib ,
Repotrectinib (ROS1, TRK, ALK),
Selpercatinib (VEGFR, FGFR),
Vandetanib (VEGFR, EGFR).
Non-receptor
Other